Sachdev Vandana, Sharma Kavita, Keteyian Steven J, Alcain Charina F, Desvigne-Nickens Patrice, Fleg Jerome L, Florea Viorel G, Franklin Barry A, Guglin Maya, Halle Martin, Leifer Eric S, Panjrath Gurusher, Tinsley Emily A, Wong Renee P, Kitzman Dalane W
J Am Coll Cardiol. 2023 Apr 18;81(15):1524-1542. doi: 10.1016/j.jacc.2023.02.012. Epub 2023 Mar 21.
Heart failure with preserved ejection fraction (HFpEF) is one of the most common forms of heart failure; its prevalence is increasing, and outcomes are worsening. Affected patients often experience severe exertional dyspnea and debilitating fatigue, as well as poor quality of life, frequent hospitalizations, and a high mortality rate. Until recently, most pharmacological intervention trials for HFpEF yielded neutral primary outcomes. In contrast, trials of exercise-based interventions have consistently demonstrated large, significant, clinically meaningful improvements in symptoms, objectively determined exercise capacity, and usually quality of life. This success may be attributed, at least in part, to the pleiotropic effects of exercise, which may favorably affect the full range of abnormalities-peripheral vascular, skeletal muscle, and cardiovascular-that contribute to exercise intolerance in HFpEF. Accordingly, this scientific statement critically examines the currently available literature on the effects of exercise-based therapies for chronic stable HFpEF, potential mechanisms for improvement of exercise capacity and symptoms, and how these data compare with exercise therapy for other cardiovascular conditions. Specifically, data reviewed herein demonstrate a comparable or larger magnitude of improvement in exercise capacity from supervised exercise training in patients with chronic HFpEF compared with those with heart failure with reduced ejection fraction, although Medicare reimbursement is available only for the latter group. Finally, critical gaps in implementation of exercise-based therapies for patients with HFpEF, including exercise setting, training modalities, combinations with other strategies such as diet and medications, long-term adherence, incorporation of innovative and more accessible delivery methods, and management of recently hospitalized patients are highlighted to provide guidance for future research.
射血分数保留的心力衰竭(HFpEF)是最常见的心力衰竭形式之一;其患病率在上升,预后在恶化。受影响的患者常经历严重的劳力性呼吸困难和使人衰弱的疲劳,以及生活质量差、频繁住院和高死亡率。直到最近,大多数针对HFpEF的药物干预试验的主要结果均为中性。相比之下,基于运动的干预试验一直表明,在症状、客观测定的运动能力以及通常的生活质量方面有巨大、显著且具有临床意义的改善。这种成功至少部分可归因于运动的多效性作用,运动可能对导致HFpEF运动不耐受的一系列异常情况(外周血管、骨骼肌和心血管方面)产生有利影响。因此,本科学声明批判性地审视了目前关于基于运动的疗法对慢性稳定HFpEF的影响、运动能力和症状改善的潜在机制,以及这些数据与其他心血管疾病运动疗法的比较。具体而言,本文回顾的数据表明,与射血分数降低的心力衰竭患者相比,慢性HFpEF患者通过监督运动训练在运动能力方面的改善幅度相当或更大,尽管医疗保险报销仅适用于后一组患者。最后,强调了在为HFpEF患者实施基于运动的疗法方面的关键差距,包括运动环境、训练方式、与饮食和药物等其他策略的联合、长期依从性、采用创新且更易获得的实施方法以及对近期住院患者的管理,以为未来研究提供指导。